Role of the endocannabinoid system in metabolic control

Current Opinion in Nephrology and Hypertension

Volumn 17, Issue 1, 2008, Pages 1-10

  Wang, Jun ^a,b   Ueda, Natsuo ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Cannabinoid receptor; Endocannabinoid; N oleoylethanolamine; Obesity; Rimonabant

Indexed keywords

2 ARACHIDONOYLGLYCEROL; AM 1387; ANANDAMIDE; CANNABINOID 1 RECEPTOR ANTAGONIST; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LH 21; N OLEOYLETHANOLAMINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RIMONABANT; TARANABANT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANOREXIA; CENTRAL NERVOUS SYSTEM; CHEMICAL STRUCTURE; CLINICAL TRIAL; DIARRHEA; DIZZINESS; ENERGY BALANCE; FOOD INTAKE; HUMAN; INSOMNIA; LIPID METABOLISM; METABOLIC REGULATION; NAUSEA; OBESITY; PRIORITY JOURNAL; REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ANOREXIA; CENTRAL NERVOUS SYSTEM; ENDOCANNABINOIDS; ETHANOLAMINES; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES;

EID: 37349023167     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e3282f29071     Document Type: Review

References (105)

1. Gaoni Y, Mechoulam R. Isolation, structure, and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964; 86:1646-1647.
2. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004; 3:771-784.
3. Matsuda LA, Lolait SJ, Brownstein MJ, et al. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346:561-564.
4. Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365:61-65.
5. Cota D, Marsicano G, Tschöp M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112:423-431.
6. Spoto B, Fezza F, Parlongo G, et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006; 88:1889-1897. • This is the first report of functional analysis of anandamide and 2-AG in human adipose tissue.
7. Osei-Hyiaman D, DePetrillo M, Pacher P, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115:1298-1305.
8. 2+ signals and insulin secretion in pancreatic β-cell. Cell Calcium 2006; 39:155-162. • This is the first report of both CB1 and CB2 expression in endocrine pancreatic cells.
9. Kulkarni-Narla A, Brown DR. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res 2000; 302:73-80.
10. 2 receptors. Science 2005; 310:329-332.
11. Gong JP, Onaivi ES, Ishiguro H, et al. Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res 2006; 1071:10-23. • This article reported a wide distribution of CB2 in mouse brain, which suggested reevaluation of possible roles of CB2 in CNS.
12. Begg M, Pacher P, Bátkai S, et al. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106:133-145.
13. Baker D, Pryce G, Davies WL, Hiley CR. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006; 27:1-4.
14. Mackie K, Stella N. Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J 2006; 8:E298-E306. • This review article supplied several lines of evidence that suggested the existence of additional cannabinoid receptors distinct from CB1 and CB2.
15. Devane WA, Hanus L, Breuer A, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992; 258:1946-1949.
16. Mechoulam R, Ben-Shabat S, Hanus L, et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995; 50:83-90.
17. Sugiura T, Kondo S, Sukagawa A, et al. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995; 215:89-97.
18. Pagotto U, Marsicano G, Cota D, et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006; 27:73-100. •• This is an intensive review of the role of endocannabinoids in the regulation of food intake and peripheral metabolism. The experimental results in this field are summarized.
19. Howlett AC. Cannabinoid receptor signaling. Handb Exp Pharmacol 2005; 168:53-79.
20. Piomelli D. The molecular logic of endocannabinoid signaling. Nat Rev Neurosci 2003; 4:873-884.
21. Matias I, Di Marzo V. Endocannabinoid synthesis and degradation, and their regulation in the framework of energy balance. J Endocrinol Invest 2006; 29:15-26. • This article reviewed not only strong evidence for a major role of the ECS in the control of energy balance, but also recent findings on alteration of the endocannabinoid tone by unbalanced energy homeostasis.
22. 2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners. J Biol Chem 2007; 282:3614-3623. •• This article reports discovery of a calcium-independent N-acyltransferase in animal tissues.
23. Okamoto Y, Morishita J, Tsuboi K, et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004; 279:5298-5305.
24. Wang J, Okamoto Y, Morishita J, et al. Functional analysis of the purified anandamide-generating phospholipase D as a member of the metallo-β-lactamase family. J Biol Chem 2006; 281:12325-12335. • NAPE-PLD was extensively characterized as a member of the metallo-β- lactamase family with a highly purified recombinant enzyme from E.coli.
25. 2 and lysophospholipase D. Biochem J 2004; 380:749-756.
26. Leung D, Saghatelian A, Simon GM, Cravatt BF. Inactivation of N-acyl phosphatidylethanolamine phospholipase D reveals multiple mechanisms for the biosynthesis of endocannabinoids. Biochemistry 2006; 45:4720-4726. • The study revealed the existence of NAPE-PLD-independent pathways for the formation of anandamide by the analysis of NAPE-PLD-deficient mice.
27. Simon GM, Cravatt BF. Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for α/β- hydrolase 4 in this pathway. J Biol Chem 2006; 281:26465-26472.
28. Liu J, Wang L, Harvey-White J, et al. A biosynthetic pathway for anandamide. Proc Natl Acad Sci U S A 2006; 103:13345-13350. • This article reported a novel NAPE-PLD-independent pathway for the anandamide formation in lipopolysaccharide-stimulated RAW264.7 macrophage cells and mouse brain.
29. McKinney MK, Cravatt BF. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 2005; 74:411-432.
30. Wei BQ, Mikkelsen TS, McKinney MK, et al. A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 2006; 281:36569-36578.
31. Tsuboi K, Sun Y-X, Okamoto Y, et al. Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 2005; 280:11082-11092.
32. Tsuboi K, Zhao L-Y, Okamoto Y, et al. Predominant expression of lysosomal N-acylethanolamine-hydrolyzing acid amidase in macrophages revealed by immunochemical studies. Biochim Biophys Acta 2007; 1771:623-632. • The article reported for the first time immunochemical studies on NAAA and revealed its predominant expression in macrophage cells.
33. Prescott SM, Majerus PW. Characterization of 1,2-diacylglycerol hydrolysis in human platelets. Demonstration of an arachidonoyl-monoacylglycerol intermediate. J Biol Chem 1983; 258:764-769.
34. Bisogno T, Howell F, Williams G, et al. Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 2003; 163:463-468.
35. 2+ dependency for triggering retrograde endocannabinoid signal. Neuron 2005; 45:257-268.
36. Bisogno T, Cascio MG, Saha B, et al. Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 2006; 1761:205-212. • The first potent and specific inhibitors of DAGL were reported in this article.
37. Uchigashima M, Narushima M, Fukaya M, et al. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci 2007; 27:3663-3676.
38. Sugiura T, Kishimoto S, Oka S, Gokoh M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Prog Lipid Res 2006; 45:405-446. •• This is a comprehensive review article on 2-AG. Its physiological significance as endocannabinoid is discussed.
39. Dinh TP, Kathuria S, Piomelli D. RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol. Mol Pharmacol 2004; 66:1260-1264.
40. Hashimotodani Y, Ohno-Shosaku T, Kano M. Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus. J Neurosci 2007; 27:1211-1219. • The article revealed the important role of MAGL in determining basal endocannabinoid tone and terminating retrograde endocannabinoid signaling in hippocampus.
41. Harrold JA, Elliott JC, King PJ, et al. Down-regulation of cannabinoid-1 (CB-1) receptors in specific extrahypothalamic regions of rats with dietary obesity: a role for endogenous cannabinoids in driving appetite for palatable food? Brain Res 2002; 952:232-238.
42. Burdyga G, Lal S, Varro A, et al. Expression of cannabinoid CB1 receptors by vagal afferent neurons is inhibited by cholecystokinin. J Neurosci 2004; 24:2708-2715.
43. Burdyga G, Varro A, Dimaline R, et al. Ghrelin receptors in rat and human nodose ganglia: putative role in regulating CB-1 and MCH receptor abundance. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1289-G1297.
44. Di Marzo V, Goparaju SK, Wang L, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Naure 2001; 410:822-825.
45. Malcher-Lopes R, Di S, Marcheselli VS, et al. Opposing crosstalk between leptin and glucocorticoids rapidly modulates synaptic excitation via endocannabinoid release. J Neurosci 2006; 26:6643-6650.
46. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136:550-557.
47. Tucci SA, Rogers EK, Korbonits M, Kirkham TC. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin. Br J Pharmacol 2004; 143:520-523.
48. 1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake. Endocrinology 2004; 145:3224-3231.
49. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58:389-462. •• This is a comprehensive overview on the current knowledge of the ECS as a target of pharmacotherapy.
50. Woods SC. The endocannabinoid system: mechanisms behind metabolic homeostasis and imbalance. Am J Med 2007; 120:S9-S17. • This article is an intensive review of the role of ECS in the metabolic homeostasis and imbalance.
51. Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. J Neurochem 2006; 98:408-419. • This article reported for the first time that anandamide administration potentiates neurotransmission in the mesolimbic dopamine reward system.
52. Melis T, Succu S, Sanna F, et al. The cannabinoid antagonist SR141716A (Rimonabant) reduces the increase of extra-cellular dopamine release in the rat nucleus accumbens induced by a novel high palatable food. Neurosci Lett 2007; 419:231-235.
53. Matias I, Gonthier M-P, Orlando P, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocr Metab 2006; 91:3171-3180. • This is the first report to show overactivity of the ECS in several peripheral cells and organs during obesity and hyperglycaemia, and in the adipose tissue of obese patients.
54. Roche R, Hoareau L, Bes-Houtmann S, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006; 126:177-187. • This is a report revealing the functional expression of CB receptors in human adipocytes.
55. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obesity 2005; 29:183-187.
56. Gómez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002; 22:9612-9617.
57. Jbilo O, Ravinet-Trillou C, Arnone M, et al. The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 2005; 19:1567-1569.
58. Engeli S, Böhnke J, Feldpausch M, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54:2838-2843.
59. Blüher M, Engeli S, Klöting N, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55:3053-3060. • This paper showed the close relationship between abdominal obesity and dysregulation of the peripheral ECS in human.
60. Yan ZC, Liu DY, Zhang LL, et al. Exercise reduces adipose tissue via cannabinoid receptor type 1 which is regulated by peroxisome proliferator-activated receptor-δ. Biochem Biophys Res Commun 2007; 354:427-433. • The article indicated that high-fat diet-induced hypertrophy of adipocytes is associated with increased CB1 expression, which is directly regulated by PPAR-δ.
61. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001; 60:329-339.
62. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003; 63:908-914.
63. Gary-Bobo M, Elachouri G, Scatton B, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006; 69:471-478. • In this paper rimonabant was reported to inhibit the proliferation of preadipocyte cells and to induce adipocyte late maturation without fat accumulation.
64. Gary-Bobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesityassociated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology 2007; 46:122-129. • This article reported the hepatoprotective role of rimonabant which reversed and prevented steatohepatitis and metabolic syndrome-related features.
65. Cavuoto P, McAinch AJ, Hatzinikolas G, et al. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007; 267:63-69. • This study examined the effects of endocannabinoids on the expression of genes regulating energy metabolism in human skeletal muscle.
66. Bermúdez-Silva FJ, Serrano A, Diaz-Molina FJ, et al. Activation of cannabinoid CB1 receptors induces glucose intolerance in rats. Eur J Pharmacol 2006; 531:282-284. • This study showed that CB1 receptor activation reduces insulin sensitivity in rats.
67. 2 receptors in glucose homeostasis in rats. Eur J Pharmacol 2007; 565:207-211. • This article reported an in-vivo study on the role of CB2 in glucose homeostasis.
68. Vickers SP, Webster LJ, Wyatt A, et al. Preferential effects of the cannabinoid CB1 receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 2003; 167:103-111.
69. Gadde KM, Allison DB. Cannabinoid-1 receptor antagonist, rimonabant, for management of obesity and related risks. Circulation 2006; 114:974-984.
70. Bray GA, Ryan DH. Drug treatment of the overweight patient. Gastroenterology 2007; 132:2239-2252.
71. Van Gaal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397.
72. Després J-P, Golay A, Sjöström L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. New Engl J Med 2005; 353:2121-2134.
73. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006; 295:761-775. •• This is the first report on a 2-year clinical trial of rimonabant. The efficacy and safety of rimonabant were described.
74. Scheen AJ, Finer N, Hollander P, et al. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006; 368:1660-1672. •• This important clinical study showed the effectiveness of rimonabant not only on weight loss but also on improvement of HbA1c levels in obese patients with type 2 diabetes.
75. Hollander P. Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus. Am J Med 2007; 120:S18-S28.
76. European Medicines Agency. Acomplia: summary of product characteristics. London: European Medicines Agency; July 14, 2006. http://www.emea.eu.int/ humandocs/PDFs/EPAR/acomplia/H-666-Pl-en%20.pdf. [Accessed August 10, 2006]
77. Bifulco M, Grimaldi C, Gazzerro P, et al. Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol Pharmacol 2007; 71:1445-1456. • This article reviewed the pleiotropic effects of rimonabant from both preclinical and clinical research works.
78. Croci T, Zarini E. Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br J Pharmacol 2007; 150:559-566.
79. Teixeira-Clerc F, Julien B, Grenard P, et al. CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat Med 2006; 12:671-676.
80. Sarnataro D, Pisanti S, Santoro A, et al. The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits human breast cancer cell proliferation through a lipid raft-mediated mechanism. Mol Pharmacol 2006; 70:1298-1306.
81. Melis MR, Succu S, Mascia MS, et al. The cannabinoid receptor antagonist SR-141716A induces penile erection in male rats: involvement of paraventricular glutamic acid and nitric oxide. Neuropharmacology 2006; 50:219-228.
82. Succu S, Mascia MS, Sanna F, et al. The cannabinoid CB1 receptor antagonist SR141716 induces penile erection by increasing extra-cellular glutamic acid in the paraventricular nucleus of male rats. Behav Brain Res 2006; 169:274-281.
83. Pavon FJ, Bilbao A, Hernández-Folgado L, et al. Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole - LH 21. Neuropharmacology 2006; 51:358-366. • This article showed that a new CB1 antagonist, LH 21, offered a potential advantage for the treatment of obesity due to its reduced unwanted side effects.
84. Fong TM, Guan X-M, Marsh DJ, et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4- chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl) pyridin-2-yl]oxy}propanamide (MK-0364), in rodents. J Pharmacol Exp Ther 2007; 321:1013-1022. • This article revealed that a novel highly potent and selective CB1 inverse agonist, MK-0364, is orally active in rodent models and has the potential to be a new agent for the treatment of obesity.
85. McLaughlin PJ, Qian L, Wood JT, et al. Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav 2006; 83:396-402.
86. Price MR, Baillie GL, Thomas A, et al. Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 2005; 68:1484-1495.
87. Horswill JG, Bali U, Shaaban S, et al. PSNCBAM-1, a novel allosteric antagonist at cannabinoid CB1 receptors with hypophagic effects in rats. Br J Pharmacol 2007; 25 Jun; [Epub ahead of print].
88. Lo Verme J, Gaetani S, Fu J, et al. Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci 2005; 62:708-716.
89. Rodríguez de Fonseca F, Navarro M, Gómez R, et al. An anorexic lipid mediator regulated by feeding. Nature 2001; 414:209-212.
90. Nielsen MJ, Petersen G, Astrup A, Hansen HS. Food intake is inhibited by oral oleoylethanolamide. J Lipid Res 2004; 45:1027-1029.
91. Fu J, Gaetani S, Oveisi F, et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-α. Nature 2003; 425:90-93.
92. Fu J, Oveisi F, Gaetani S, et al. Oleoylethanolamide, an endogenous PPAR-α agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology 2005; 48:1147-1153.
93. Guzmán M, Lo Verme J, Fu J, et al. Oleoylethanolamide stimulates lipolysis by activating the nuclear receptor peroxisome proliferator-activated receptor α (PPAR-α). J Biol Chem 2004; 279:27849-27854.
94. Yang Y, Chen M, Georgeson KE, Harmon CM. Mechanism of oleoylethanolamide on fatty acid uptake in small intestine after food intake and body weight reduction. Am J Physiol Regul Integr Comp Physiol 2007; 292:R235-R241.
95. González-Yanes C, Serrano A, Bermúdez-Silva FJ, et al. Oleylethanolamide impairs glucose tolerance and inhibits insulin-stimulated glucose uptake in rat adipocytes through p38 and JNK MAPK pathways. Am J Physiol Endocrinol Metab 2005; 289:E923-E929.
96. Su H-F, Samsamshariat A, Fu J, et al. Oleylethanolamide activates Ras-Erk pathway and improves myocardial function in doxorubicin-induced heart failure. Endocrinology 2006; 147:827-834.
97. Astarita G, Di Giacomo B, Gaetani S, et al. Pharmacological characterization of hydrolysis-resistant analogs of oleoylethanolamide with potent anorexiant properties. J Pharmacol Exp Ther 2006; 318:563-570. • This article described that the hydrolysis-resistant analogs of N-oleoylethanolamine, through PPAR-α activation, persistently reduced feeding in rodents, which provided a starting point for the development of novel anti-obesity drugs.
98. Serrano A, del Arco I, Javier Pavón F, et al. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats. Neuropharmacology 2007; 24 Mar [Epub ahead of print]. • The study examined the metabolic effect of a combination of rimonabant and N-oleoylethanolamine on obese Zucker rats.
99. Ahern GP. Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 2003; 278:30429-30434.
100. 1) agonists. J Biol Chem 2005; 280:38496-38504.
101. Overton HA, Babbs AJ, Doel SM, et al. Deorphanization of a G protein-coupled receptor for oleoylethanolamide and its use in the discovery of small-molecule hypophagic agents. Cell Metab 2006; 3:167-175. •• This study revealed that N-oleoylethanolamine is an agonist of the GPR119 receptor, and its selective agonist was shown to suppress feeding and reduce body weight gain and adiposity in rat models.
102. Petersen G, Sørensen C, Schmid PC, et al. Intestinal levels of anandamide and oleoylethanolamide in food-deprived rats are regulated through their precursors. Biochim Biophys Acta 2006; 1761:143-150. • The authors offer evidence that endogenous levels of anandamide and N-oleoylethanolamine in rat intestine depend on the relative abundance of their biosynthetic precursors.
103. Fu J, Astarita G, Gaetani S, et al. Food intake regulates oleoylethanolamide formation and degradation in the proximal small intestine. J Biol Chem 2007; 282:1518-1528. • This article revealed that food intake promoted N-oleoylethanolamine mobilization in the mucosal layer of the rodent proximal small intestine through the concerted regulation of its biosynthesis and degradation.
104. LoVerme J, Guzmán M, Gaetani S, Piomelli D. Cold exposure stimulates synthesis of the bioactive lipid oleoylethanolamide in rat adipose tissue. J Biol Chem 2006; 281:22815-22818.
105. Rubio M, McHugh D, Fernández-Ruiz J, et al. Short-term exposure to alcohol in rats affects brain levels of anandamide, other N-acylethanolamines and 2-arachidonoyl-glycerol. Neurosci Lett 2007; 421:270-274.